Table 2 Reported proportions of categorical change from baseline at month 1 in BCVA in patients with BRVO and CRVO on dexamethasone and sham
BRVO | CRVO | |||||
|---|---|---|---|---|---|---|
Improvement or worsening at month 1 | Dexamethasone (n1 = 291) | Sham (n2 = 279) | Relative risk* (95% CI)‡ | Dexamethasone (n1 = 136) | Sham (n2 = 147) | Relative risk* (95% CI)‡ |
Gain ≥15 letters | 0.213 | 0.079 | 2.70 (1.71, 4.27) | 0.213 | 0.068 | 3.13 (1.59, 6.19) |
Gain ≥5 and <15 letters | 0.474 | 0.369 | 1.28 (1.06, 1.56) | 0.412 | 0.245 | 1.68 (1.19, 2.38) |
Loss <5 letters and gain <5 letters | 0.258 | 0.441 | 0.58 (0.46, 0.74) | 0.301 | 0.483 | 0.62 (0.46, 0.85) |
Loss ≥5 letters and <15 letters | 0.055 | 0.097 | 0.57 (0.31, 1.03) | 0.037 | 0.136 | 0.27 (0.10, 0.70) |
Loss ≥15 letters | 0.000 | 0.014 | 0.000 (0.00, 0.00) | 0.037 | 0.068 | 0.54 (0.19, 1.54) |
Gain ≥10 letters | 0.426 | 0.201 | 2.12 (1.62, 2.78) | 0.456 | 0.122 | 3.74 (2.33, 5.96) |
Mean improvement (letters)¶ | 8.5 | 3.8 | 7.2 | 0.4 | ||
SD improvement§ | 7.916 | 7.916 | 10.721 | 10.721 | ||